BB Biotech

Industry Voice: Biotech companies are increasingly pioneering groundbreaking therapies for diseases with high unmet medical need. Investing in these innovation leaders is a hallmark of BB Biotech'sinvestment philosophy.

INDUSTRY VOICE: Despite market volatility in Q1, BB Biotech performed very well with an overall return of 8.8% in CHF. Several large biotech companies are currently trading below their fundamental value,and offer an attractive entry level for investors....

With a total return of 23.1% in CHF and 13.1% in EUR buoyed by the euro's substantial appreciation against the dollar, BB Biotech delivered a strong performance in 2017 and will propose a record regular dividend of CHF 3.30 per share .

The biotech sector has been churning out a new generation of drug treatment options.

At a recent American Society for Clinical Oncology (ASCO) conference investors were able to review progress in immunotherapy clinical trials. The progress is positive. Incyte, for one, presented improved patient response rates in five types of cancer...

BB Biotech's Head of Investment, Daniel Koller, explains why the sector's fundamentals are all lined up to the upside.

Head of Investment at BB Biotech, Daniel Koller, discusses sector growth and the attractive valuations of fast growing companies.

A Q&A with BB Biotech's Head of Investment Management Daniel Koller reveals how innovation in medicine is offering investment opportunities.

Despite the uncertainty on the political front and the macroeconomic unknowns, the biotech sector's fundamentals have remained solid.

Focus guide on BB Biotech